Tagrisso Tablet, Film Coated
Product Images NDC 0310-1349

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tagrisso (NDC 0310-1349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tagrisso 40 mg Tablet Bottle Label

Label for Tagrisso (osimertinib) tablets, 40 mg per tablet, presented in a package of 30 tablets. The label shows that it is a prescription drug manufactured by AstraZeneca Pharmaceuticals LP, with manufacturing locations in Wilmington, DE, USA, and Södertälje, Sweden. The AstraZeneca logo is visible on the label.*

FDA Label Image

Tagrisso 80 mg Tablet Bottle Label

Label for Tagrisso (osimertinib) tablets, 80 mg per tablet, oral dosage form. The label indicates a package size of 30 tablets and shows the NDC number 0310-1350-30. Manufactured by AstraZeneca Pharmaceuticals LP with manufacturing locations in Sweden and Switzerland, the label includes the AstraZeneca logo and states the drug is prescription-only.*

FDA Label Image

Chem_structure (Chemical Structure)

Chemical structure of osimertinib, the active ingredient in TAGRISSO tablets, depicted as a 2D molecular diagram showing its atomic and bonding arrangement.*

FDA Label Image

Figure 1 Adaura

A Kaplan-Meier survival curve chart comparing the probability of disease-free survival over time (months) between TAGRISSO (osimertinib) and placebo groups. The x-axis shows time from randomization in months, and the y-axis shows the probability of disease-free survival. The chart includes numbers of subjects at risk at various time points for both groups, with TAGRISSO showing higher survival probability over the observed period.*

FDA Label Image

Figure 2

A Kaplan-Meier plot showing the probability of progression-free survival over time from randomisation (months) comparing TAGRISSO (osimertinib) and EGFR TKI treatments. The y-axis represents the probability of progression-free survival from 0 to 1.0, and the x-axis shows months from 0 to 27. The TAGRISSO group demonstrates higher survival probability than the EGFR TKI group throughout the study period. Below the graph, the number of patients at risk at several time points for each group is listed, with censored patients marked by plus signs on the curves.*

FDA Label Image

Figure 3

A Kaplan-Meier survival curve comparing overall survival probability over time (months) from randomization between TAGRISSO (osimertinib) and EGFR TKI groups. The graph shows survival probabilities on the vertical axis and time in months on the horizontal axis, with TAGRISSO represented by a solid line and EGFR TKI by a dashed line. A table below indicates the number of patients at risk at various time points with censored patients marked by plus signs on the curves.*

FDA Label Image

Figure 4

Kaplan-Meier survival curve comparing the probability of progression-free survival over time (in months) between TAGRISSO (osimertinib) and chemotherapy groups. The graph shows a higher progression-free survival probability for TAGRISSO across the studied period up to 18 months. The number of patients at risk at various time points is displayed below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.